Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
54Gene
AddedFeb 15, 2024
UpdatedJun 18, 2026
54Gene

54Gene

Acquired

54gene: Advancing precision medicine globally with African genomics.

HQ
Washington, D.C., DC, US
Founded
2019
Accelerator
Y Combinator logoY CombinatorW19
Overview
Compare
Fundraising
Employees
Website

Founded in 2019, 54Gene is an African genomics research, services, and development company with a mission to advance precision medicine globally by including under-represented African genomic data in research. The company aims to drive medical breakthroughs and new healthcare solutions by focusing on the unique genetic diversity found within African populations. 54Gene offers genomic sequencing, bioinformatics, and data analytics services, targeting both African and global markets to enhance the inclusivity and accuracy of medical research.

Notable figures affiliated with 54Gene include its founder and CEO, Dr. Abasi Ene-Obong. The company has attracted significant investment from prominent venture capital firms such as Y Combinator and Adjuvant Capital. Key achievements include raising substantial funding rounds and establishing partnerships with leading research institutions. 54Gene's impact lies in its potential to revolutionize healthcare by ensuring that African genomic data is adequately represented in global medical research, thereby contributing to more effective and inclusive healthcare solutions worldwide.

54Gene - Similar Companies

Nest Genomics logo

Nest Genomics

nestgenomics.com

Genetica logo

Genetica

genetica.asia

IndyGeneUS AI logo

IndyGeneUS AI

indygeneus.ai

Genome Medical logo

Genome Medical

genomemedical.com

GeneDx Holdings logo

GeneDx Holdings

genedx.com

Yemaachi Biotechnology logo

Yemaachi Biotechnology

yemaachi.com

Singular Genomics logo

Singular Genomics

Unite Genomics logo

Unite Genomics

Base5 Genomics logo

Base5 Genomics

b5genomics.com

Genomenon logo

Genomenon

genomenon.com

Genomelink logo

Genomelink

genomelink.io

Probably Genetic logo

Probably Genetic

Geneicd logo

Geneicd

Geneial logo

Geneial

geneial.com

Gencove logo

Gencove

gencove.com

54Gene - Quick Facts

Who are 54Gene's competitors?

Companies similar to 54Gene include Nest Genomics, Genetica, IndyGeneUS AI and Genome Medical.

When was 54Gene founded?

54Gene was founded in 2019.

Where is 54Gene's headquarters located?

54Gene's headquarters is located in Washington, D.C., DC, US.

When was 54Gene's last funding round?

54Gene's most recent funding round was for $50M (USD) in October 2022.

How much has 54Gene raised to-date?

As of Oct 28, 2022, 54Gene has raised a total of $94.7M (USD).

54Gene - Classification

Ownership
  • Private Equity
  • Venture Capital
Technology
  • Biotech
  • Data
Geographic Exposure
  • Global
Revenue
  • Recurring
Main Product
  • Genomics
  • Research
Tags
  • Consulting
  • Platform
  • Research
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified